June 07, 2022
Ruxolitinib and chemotherapy appeared to boost progression-free survival in patients with stage III and IV ovarian cancer when given before or after surgery.
June 06, 2022
Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.
June 06, 2022
Patients with platinum-sensitive ovarian cancer treated with maintenance rucaparib in the ATHENA-MONO trial showed a significant improvement in progression-free survival when compared with placebo in the first-line setting, regardless of HRD status.
May 23, 2022
Priority review to a biologics license application has been granted by the FDA for mirvetuximab soravtansine to treat patients with folate receptor alpha-high platinum-resistant ovarian cancer.
May 19, 2022
A new murine monoclonal antibody B43.12 is under investigation in combination with paclitaxel and carboplatin as a treatment option for patients with advanced epithelial ovarian cancer.
May 18, 2022
An individualized starting dose of niraparib, determined by weight and platelet count, continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status,
May 17, 2022
Eric Pujade-Lauraine, MD, PhD, discusses the prognostic factors researchers are looking for when testing patients with ovarian cancer.
May 08, 2022
Barbara Buttin, MD, covers the past and present standards of care, as well as upcoming therapeutic options, for World Ovarian Cancer Day.
April 27, 2022
During a Targeted Oncology case-based roundtable event, Thomas C. Krivak, MD, discussed the results of studies of PARP inhibition for patients with advanced ovarian cancer.
April 26, 2022
The FDA has granted fast track designation to ofranergene obadenovec in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer. The agent is under investigation in the phase 3 OVAL study.